loading page

Population pharmacokinetic-pharmacodynamic model of subcutaneous bupivacaine in a novel extended-release microparticle formulation
  • +6
  • Ida Storgaard,
  • Elisabeth Kjær Jensen,
  • Søren Bøgevig,
  • Torben Balchen,
  • Anders Holten Springborg,
  • Mike Allan Royal,
  • Kirsten Møller,
  • Mads Utke Werner,
  • Trine Lund
Ida Storgaard
University of Copenhagen
Author Profile
Elisabeth Kjær Jensen
Department of Anesthesia Pain and Respiratory Support Neuroscience Center
Author Profile
Søren Bøgevig
Copenhagen University Hospitals
Author Profile
Torben Balchen
Copenhagen University Hospitals
Author Profile
Anders Holten Springborg
Department of Anesthesia Pain and Respiratory Support Neuroscience Center
Author Profile
Mike Allan Royal
Liquidia Corporation Inc
Author Profile
Kirsten Møller
Copenhagen University Hospital-Rigshospitalet
Author Profile
Mads Utke Werner
Department of Anesthesia Pain and Respiratory Support Neuroscience Center
Author Profile
Trine Lund
University of Copenhagen

Corresponding Author:[email protected]

Author Profile

Abstract

The objective of this study was to develop a population pharmacokinetic-pharmacodynamic model of subcutaneously administered bupivacaine in a novel extended release microparticle formulation for postoperative pain management. Bupivacaine was administered subcutaneously in the lower leg to 28 healthy male subjects in doses from 150 to 600 mg in a phase 1 randomized, placebo-controlled, double-blind, dose-ascending study with two different compositions of microparticle formulations called LIQ865. Population pharmacokinetic-pharmacodynamic models were fitted to plasma concentration-effect-time data using non-linear mixed-effects modeling. The pharmacokinetics were best described by a two-compartment model with biphasic absorption as two parallel absorption processes: a fast, zero-order process and a slower, first-order process with two transit compartments. The slow absorption process was found to be dose-dependent and rate-limiting for bupivacaine clearance at higher doses. Bupivacaine clearance and the transit rate constant describing the slow absorption process both decreased with increasing doses following a power function with a shared covariate effect of dose on the two parameters. The pharmacokinetic-pharmacodynamic relationship between plasma concentrations and effect was best described by a linear function. This model gives new insight into the pharmacokinetics and pharmacodynamics of microparticle formulations of bupivacaine, and the biphasic absorption seen for several local anesthetics.
Submitted to Basic & Clinical Pharmacology & Toxicology
27 Jan 2024Review(s) Completed, Editorial Evaluation Pending
27 Jan 2024Editorial Decision: Revise Minor
27 Feb 2024Assigned to Editor
27 Feb 2024Submission Checks Completed
27 Feb 2024Review(s) Completed, Editorial Evaluation Pending
27 Feb 2024Editorial Decision: Accept